Analysing alternatives, page-6

I remember reading that most of the Patients came from the Eastern Bloc. There were NO trial sites in the US because there was NO screening for KRAS- that was apparently a requirement for US trial sites, which would of bumped up the costs/ slowed down the recruitment process. So they basically used cheaper EU recruitment instead.

Although KRAS status should be irrespective of HA-I, it might turn out to of still been an important biomarker in establishing a patients prospects for success using HA-I. Eg patients with the KRAS mutant gene, who didn't have access to Avastin( bevacizumab), might show different responses in 2nd line treatment than those with the KRAS mutant gene, who were treated with Avastin in 1st line.

Don't get too caught on Avastin yet, it might not have anything to do with the botched trial. It's all speculation.